Psoriasis News and Research

Latest Psoriasis News and Research

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

Idera Pharmaceuticals receives patent related to IMO-8400

Idera Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics International announced today that it has raised $9.6 million in current financing round.

18 Jul 2013

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

The National Psoriasis Foundation awarded Zelma Chiesa Fuxench, M.D., of the University of Pennsylvania, its inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship, recognizing her work as a promising psoriasis and psoriatic arthritis researcher.

9 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis.

3 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio AB announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

26 Jun 2013

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Fibromyalgia, a painful condition affecting approximately 10 million people in the U.S., is not imaginary after all, as some doctors have believed. A discovery, published this month in PAIN MEDICINE (the journal of the American Academy of Pain Medicine), clearly now demonstrates that fibromyalgia may have a rational biological basis located in the skin.

19 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis.

13 Jun 2013

Psoriasis News and Research

Latest Psoriasis News and Research

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Idera Pharmaceuticals receives patent related to IMO-8400

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Psoriasis News and Research

Latest Psoriasis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in